XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
2.780
+0.018 (0.65%)
At close: Aug 21, 2026, 4:00 PM EDT
2.660
-0.120 (-4.32%)
After-hours: Aug 21, 2026, 7:15 PM EDT

XTL Biopharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
77225615
Market Cap Growth
-43.41%-68.18%322.69%-16.65%-57.56%-4.50%
Enterprise Value
67213212
Last Close Price
2.782.328.104.044.8411.08

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----34.41
PB Ratio
--28.044.122.381.592.81
P/TBV Ratio
---2.881.763.02

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
--0.03---
Net Debt / Equity Ratio
0.300.30-0.18-0.90-0.93-1.15
Net Debt / EBITDA Ratio
0.060.061.752.634.235.95
Net Debt / FCF Ratio
0.070.070.602.844.135.84
Quick Ratio
0.180.180.569.7419.9026.52
Current Ratio
0.400.400.619.9320.3527.00
Return on Equity (ROE)
-29.30%-29.30%6.27%-57.31%-28.89%9.73%
Return on Assets (ROA)
-21.01%-21.01%-8.83%-14.46%-10.18%-9.82%
Return on Capital Employed (ROCE)
576.80%576.80%-12.20%-34.50%-22.00%-16.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-105.96%-97.83%-4.59%-33.65%-21.22%2.91%
FCF Yield
-15.58%-14.39%-7.47%-13.35%-14.18%-7.01%
Buyback Yield / Dilution
-52.32%-33.15%-23.52%0.00%11.48%-19.71%
SEC Filings: 10-K · 10-Q